RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00035024.xml
PDF herunterladen
Thromb Haemost 2001; 86(06): 1363-1367
DOI: 10.1055/s-0037-1616736
DOI: 10.1055/s-0037-1616736
Review Article
Endothelial Perturbation in Cystic Fibrosis
Weitere Informationen
Publikationsverlauf
Received
24. März 2001
Accepted after resubmission
06. August 2001
Publikationsdatum:
12. Dezember 2017 (online)
Summary
Cystic fibrosis (CF) is characterized by a persistent inflammatory state, which can be secondary to chronic pulmonary infection and may affect vascular endothelium. We measured circulating levels of von Willebrand factor (vWF), tissue-plasminogen activator (t-PA), and P-selectin in 20 CF patients and 20 healthy subjects. vWF, t-PA and P-selectin levels were significantly higher in CF patients. Endothelial perturbation (> 2 SD increase in both vWF and t-PA) was present in 65% of CF patients. These patients displayed lower FEV1 values compared to individuals without endothelial perturbation and an inverse correlation between FEV1 and P-selectin levels was observed. Tumor necrosis factor- (TNF-) and interleukin (IL)-6 levels were also increased in CF patients and significant direct correlations were found between TNF- and vWF, t-PA or P-selectin levels. These results indicate that CF patients exhibit signs of endothelial dysfunction/perturbation, which are likely to be related to a persistent inflammatory state due to chronic pulmonary infection, and may play a role in the progression of this disease.
-
References
- 1 FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr 1993; 122: 1-9.
- 2 Collins FS. Cystic fibrosis: molecular biology and therapeutic implications. Science 1992; 256: 774-9.
- 3 MacLusky I, Levison H. Cystic fibrosis. In: Disorders of the respiratory tract in children,. 5th ed, V. Chernick, ed. Philadelphia: W. B. Saunders; 1990: 692-729.
- 4 Rayner RJ, Wiseman MS, Cordon SM, Norman D, Hill EJ, Shale DJ. Inflammatory markers in cystic fibrosis. Resp Med 1991; 85: 139-45.
- 5 Kronborg G, Hansen MB, Svenson M, Fomsgaard A, Höiby N, Bendtzen K. Cytokines in sputum and serum from patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection as markers of destructive inflammation in the lungs. Pediatr Pulmonol 1993; 15: 292-7.
- 6 Norman D, Elborn JS, Cordon SM, Rayner RJ, Wiseman MS, Hiller EJ, Shale DJ. Plasma tumour necrosis factor alpha in cystic fibrosis. Thorax 1991; 46: 91-5.
- 7 Brown MA, Morgan WJ, Finley PR, Scuderi P. Circulating levels of tumour necrosis factor and interleukin-1 in cystic fibrosis. Pediatr Pulmonol 1991; 10: 86-91.
- 8 Nixon LS, Yung B, Bell SC, Elborn JS, Shale DJ. Circulating immunoreactive interleukin-6 in cystic fibrosis. Am J Respir Crit Care Med 1998; 157: 1764-9.
- 9 Ferro D, Pittoni V, Quintarelli C, Basili S, Saliola M, Caroselli C, Valesini G, Violi F. Coexistence of anti-phospholipid antibodies and endothelial perturbation in systemic lupus erythematosus patients with ongoing prothrombotic state. Circulation 1997; 95: 1425-32.
- 10 Mannucci PM. Von Willebrand factor a marker of endothelial damage?. Arterioscler Thromb Vasc Biol 1998; 18: 1359-62.
- 11 Stenberg PE, McEver RP, Shuman MA, Jacques YV, Bainton DF. A platelet alpha-granule membrane protein (GMP 140) is expressed to plasma membrane after activation. J Cell Biol 1985; 101: 880-6.
- 12 Bonfanti RB, Furie C, Furie B, Wagner DD. PADGEM (GMP 140) is a component of Weibel-Palade bodies of human endothelial cells. Blood 1989; 73: 1109-12.
- 13 Ikeda H, Takaio Y, Ichiki K, Ueno T, Maki S, Noda T, Sugi K, Imaizumi T. Increased soluble form of P-selectin in patients with unstable angina. Circulation 1995; 92: 1693-6.
- 14 Ikeda H, Nakayama H, Oda T, Kuwano K, Muraishi A, Sugi K, Koga Y, Toshima H. Soluble form of P-selectin in patients with acute myocardial infarction. Coron Artery Dis 1994; 5: 515-8.
- 15 Katayama M, Handa M, Araki Y, Ambo H, Kawai Y, Watanabe K, Ikeda Y. Soluble P-selectin is present in normal circulation and its plasma level is elevated in patients with thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome. Br J Haematol 1993; 84: 702-10.
- 16 Kaikita K, Ogawa H, Yasue H, Sakamoto T, Suefuji H, Sumida H, Okumura K. Soluble P-selectin is released into the coronary circulation after coronary spasm. Circulation 1995; 92: 1726-30.
- 17 Davì G, Romano M, Mezzetti A, Procopio A, Iacobelli S, Antidormi T, Bucciarelli T, Alessandrini P, Cuccurullo F, Bittolo Bon G. Increased levels of soluble P-selectin in hypercholesterolemic patients. Circulation 1998; 97: 953-7.
- 18 Stern RC. The diagnosis of cystic fibrosis. N Engl J Med 1997; 336: 487-91.
- 19 Gibson LE, Cooke RE. A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics 1959; 23: 545-9.
- 20 Schwachman H, Kulczycki L. Long term study of one hundred and five patients with cystic fibrosis. Am J Dis Child 1958; 96: 6-15.
- 21 Saiki RK, Walsh PS, Levenson CH, Erlich HA. Genetic analysis of amplified DNA with immobilized sequence-specific oligonucleotide probes. Proc Natl Acad Sci USA 1989; 86: 6230-4.
- 22 Rady M, D’Alcamo E, Seia M, Iapichino L, Ferrari M, Russo S, Romeo G, Maggio A. Simultaneous detection of fourteen italian cystic fibrosis mutations in seven exons by reverse dot-blot analysis. Mol Cell Probes 1995; 9: 357-60.
- 23 American Thoracic Society.. Standardization of spirometry – 1987 update. Am Rev Respir Dis 1987; 136: 1285-98.
- 24 Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol 1990; 6: 217-46.
- 25 Boneu B, Abbal M, Plante J, Bierme R. Factor VIII complex and endothelial damage. Lancet 1975; 1: 1430.
- 26 De Rose V, Oliva A, Messore B, Grosso B, Mollar C, Pozzi E. Circulating adhesion molecules in cystic fibrosis. Am J Respir Crit Care Med 1998; 157: 1234-9.
- 27 Boldy DA, Short PE, Cowen P, Hill FG, Chambers DC, Ayres JG. Plasma levels of von Willebrand factor antigen in acute bronchitis and in normal population. Respir Med 1998; 92: 395-400.
- 28 Ciabattoni G, Davì G, Collura M, Iapichino L, Pardo F, Ganci A, Romagnoli R, Maclouf J, Patrono C. In vivo lipid peroxidation and platelet activation in cystic fibrosis. Am J Respir Crit Care Med 2000; 162: 1195-201.
- 29 Furie B, Furie BC. The molecular basis of platelet and endothelial cell interaction with neutrophils and monocytes: role of P-selectin and the P-selectin ligand, PSGL-1. Thromb Haemost 1995; 74: 224-7.
- 30 Kahaleh MB. The role of vascular endothelium in the pathogenesis of connective tissue disease: endothelial injury, activation, participation and response. Clin Exp Rheumatol 1990; 8: 595-601.
- 31 Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?. Atherosclerosis 1999; 148: 209-14.
- 32 McCarty MF. Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes and visceral obesity: down regulation with essential fatty acids, ethanol and pentoxifyl-line. Med Hypotheses 1999; 52: 465-77.
- 33 Kube D, Sontich U, Fletcher D, Gavis PB. Proinflammatory cytokine responses to P. aeruginosa infection in human airway epithelial cell lines. Am J Physiol 2001; 280: L493-L502.
- 34 Meduri GU, Kanangat S, Stefan J, Tolley E, Schaberg D. Cytokines IL-1 beta, IL-6, and TNF-alpha enhance in vitro growth of bacteria. Am J Resp Crit Care Med 1999; 160: 961-7.